Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects
Open Access
- 2 October 2025
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (6) , 1757-1774
Abstract
Purpose Despite advancements in 177Lu-based radiotherapy for cancer, its efficacy against refractory cold tumors remains limited. Targeted peptide-radionuclide conjugates (PRCs) combined with immunotherapy are emerging as promising theranostic strategies to maximize anti-tumor effectiveness. Methods Cyclic peptide CEMJ4 was identified via phage selection, and further conjugated with DOTA and radiolabeled with 68Ga for diagnostic imaging and 177Lu for cancer therapy. The druggability was assessed by in vitro cell experiments, in vivo PET/CT imaging and biodistribution. Additionally, the feasibility of combining 177Lu-DOTA-CEMJ4 with a hematopoietic progenitor kinase 1 inhibitor (HPK1i) was evaluated in B16F10 tumor-bearing mice, focusing on the anti-tumor immune response and tumor growth. Results CEMJ4 exhibited high affinity for human erythropoietin-producing hepatocellular receptor A2 (EphA2; KD = 0.3 ± 0.2 µM), a therapeutic target overexpressed in several solid tumors. Radiolabeled 68Ga/177Lu-DOTA-CEMJ4 specifically bound to EphA2-expressing B16F10 cells and tumor models, effectively inhibiting tumor growth. Notably, 177Lu-induced T cell immunotoxicity was reversed by HPK1i, which modulated T cell dysfunction. Combining 177Lu-DOTA-CEMJ4 with HPK1i significantly reduced tumor burden and increased tumor-infiltrating CD4+ T cells, CD8+ T cells, and M1 macrophages. Conclusion This study identifies CEMJ4 as a promising peptide ligand for tumor-targeted radionuclide delivery and emphasizes the clinical potential of radionuclide therapy combined with immunotherapy in theranostics to enhance therapeutic precision and efficacy. Graphical AbstractKeywords
Funding Information
- National Natural Science Foundation of China (82173205)
This publication has 47 references indexed in Scilit:
- Peptide Ligands Stabilized by Small MoleculesAngewandte Chemie International Edition, 2014
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsInvestigational New Drugs, 2012
- Cancer immunotherapyMolecular Oncology, 2012
- Cancer and Radiation Therapy: Current Advances and Future DirectionsInternational Journal of Medical Sciences, 2012
- A modeling analysis of the effects of molecular size and binding affinity on tumor targetingMolecular Cancer Therapeutics, 2009
- A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor GrowthIn vivoCancer Research, 2008
- Eph-Ephrin Bidirectional Signaling in Physiology and DiseaseCell, 2008
- EphA2 overexpression is associated with angiogenesis in ovarian cancerCancer, 2007
- Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivoEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- The effect of conformation on the solution stability of linear vs. cyclic RGD peptidesChemical Biology & Drug Design, 1999